Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 222

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 8
Chunk 222
---
361 377,221 Amortization of intangible assets77,977 82,385 82,630 Intangible asset impairment charges— 20,189 — Contingent consideration gain(6,110)(1,517)(510)Total costs and expenses580,151 612,790 621,114 Operating earnings (loss)81,666 (5,269)46,124 Other income (expense)Interest and other income, net16,204 10,453 21,689 Interest expense— (2,415)(7,070)Total other income (expense), net16,204 8,038 14,619 Earnings before income taxes97,870 2,769 60,743 Income tax expense24,005 1,453 32 Net earnings$73,865 $1,316 $60,711 Earnings per shareBasic$1.34 $0.02 $1.13 Diluted$1.32 $0.02 $1.04 Weighted average shares outstandingBasic55,100,063 54,536,281 53,665,143 Diluted55,958,537 55,506,828 61,679,800 

(a) Excludes amortization of intangible assets.

See accompanying notes.

93

Supernus Pharmaceuticals, Inc.

Consolidated Statements of Comprehensive Earnings

(in thousands) Year Ended December 31, 202420232022Net earnings$73,865 $1,316 $60,711 Other comprehensive gain (loss)Unrealized gain (loss) on marketable securities, net of tax404 2,617 (4,749)Other comprehensive gain (loss)404 2,617 (4,749)Comprehensive earnings$74,269 $3,933 $55,962 

See accompanying notes.

94

Supernus Pharmaceuticals, Inc.

Consolidated Statements of Changes in Stockholders' Equity

(in thousands, except share data)Common StockAdditionalPaid-inCapitalAccumulatedOtherComprehensiveEarnings (Loss)RetainedEarningsTotalStockholders'Equity SharesAmountBalance, December 31, 202153,256,094 $53 $434,337 $1,539 $379,922 $815,851 Cumulative effect of